EGFR and non-small cell lung carcinoma: AhR, activated by kynurenine-tryptophan metabolized product by TDO2, bypasses EGFR to retrieve PI3K/AKT and MEK/ERK pathway leading to resistance to tyrosine kinase inhibitors in non-small cell lung cancer [32].